SLAS-ELRIG Networking Forum: Innovations in New Drug Modalities & Biologics

Innovations in New Drug Modalities & Biologics

Join SLAS and ELRIG in an extraordinary collaboration showcasing the latest pharmaceutical innovations. From revolutionary mRNA technologies to cutting-edge developments in antibodies and cell and gene therapies, immerse yourself in the dynamic evolution of drug discovery and therapeutics—experience the innovations setting the stage for a new era in medicine.

When: Tuesday, 3 December 2024

Where: The Royal Society of Medicine

Royal Society of Medicine
1 Wimpole Street
London
W1G 0AE

Purpose

This event is a junction for industry leaders, researchers, and innovators to come together, share their groundbreaking ideas and delve into the transformative developments shaping the future of drug discovery and therapeutics. By highlighting the trailblazing innovations across new drug modalities and biologics, we aim to ignite collaboration, spark ingenuity and propel progress in the pharmaceutical sector.

Keynote Speaker

Topic: Innovation and the discovery of new modality medicines – a view from MDC/UK

Chris Molloy has a 30-year international board and executive career across a unique range of life sciences R&D disciplines. He began in preclinical research at Glaxo and then held leadership roles at MerLion Pharmaceuticals, IDBS and the RSA Group. As the founding CEO of Medicines Discovery Catapult (MDC), he leads an experienced executive team and a cohort of over 130 specialists to achieve the organization’s vision of reshaping drug discovery for patient benefit.